DCAT Names Officers
Lyra Myers, associate director and value creation agent at Roche, has been elected DCAT president.
Lyra Myers, associate director and value creation agent at Roche, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT). Also elected to serve as officers of DCAT are: George Svokos, senior vice-president, product and portfolio management at Teva Pharmaceuticals U.S.A., as senior vice-president; Folker Ruchatz, senior vice-president, contract manufacturing business, biopharmaceuticals at Boehringer Ingelheim as finance officer; and Milton Boyer, president at OSO BioPharmaceuticals Manufacturing, LLC as vice-president. All will serve one-year terms.
DCAT is a nonprofit business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical, and related industries. The association provides services, programs and activities designed to support the business development objectives of its membership.
Source: DCAT
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
